Amgen (NASDAQ:AMGN) today issued the following statement on the MariTide (maridebart cafraglutide, formerly AMG 133) Phase 1 data.

Wednesday’s business headlines INDIANAPOLIS (WISH) — Here is a look at Wednesday’s business headlines with Jane ...

As the Horizon acquisition reaps its benefits, Amgen is now turning eyes to its obesity and diabetes portfolio.

Discover why Amgen is a reliable wealth compounder with strong Q3 results, a promising pipeline, debt reduction, and ...

It’s been about one year since Amgen closed its $27.8 billion Horizon Therapeutics buyout and brought the rare disease drug ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

While Amgen’s third-quarter financial results on Wednesday were “somewhat uneventful,” investors continue to be focused on ...

Amgen ( AMGN 1.68%), a leader in biotechnology, released its third-quarter 2024 financial results on Oct. 30. The company ...

UBS lowered the firm’s price target on Amgen (AMGN) to $326 from $335. Amgen reported in-line topline sales for Q3, with most products as ...

Amgen Inc ( (AMGN) ) has realeased its Q3 earnings. Here is a breakdown of the information Amgen Inc presented to its investors. Amgen Inc., a ...

Amgen reported higher quarterly earnings on Wednesday, driven by a 24% rise in sales of products including cholesterol drug ...

Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ETCompany ParticipantsJustin Claeys - VP, IRRobert Bradway - ...